High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-α plus ribavirin

Bratislava Medical Journal

Volumn 110, Issue 2, 2009, Pages 77-84

  Gazdik, F ^a   Gazdikova, K ^a   Laktis, K ^b   Okruhlica, L ^c   Fejdiova, K ^a   Danis, D ^a   Pijak, M R ^a   Wsolova, L ^a   Kajaba, I ^a   Kratky, A ^a  

^a Department of Immunology and Immunotoxicology   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c Centre for Treatment of Drug Dependencies   (Slovakia)

Author keywords

Chronic hepatitis C; Former drug users; Pegylated interferon ; Ribavirin; Sustained viral response

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOLATION AND PURIFICATION; LIVER; MALE; PATHOLOGY; PHASE 4 CLINICAL TRIAL; SUBSTANCE ABUSE; VIROLOGY;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 70349754174     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J 2002; 345: 41-52
2. El-Serag HB, Mason AC. Rising incidence of hepatocelluar carcinomain the United States. New Engl J Med 1999; 340: 745-750
3. Biggins SW, Terrault NA. Treatment of reccurent hepatitis C after liver transplantation. Clin Liver Dis 2005; 9: 505-523
4. Touzet S, Kraemer L, Colin C et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. Hencore Group (Hepatitis C Eurpean Network for Cooperative Research). Eur J Gastroenterol Hepatol 2000; 12: 667-676
5. Gazdik F, Pijak M, Gazdikova K et al. Hepatitis C virus prevalence among general population and risk groups in the Slovak Republic. Hepatology 2001; 34 (4): 559
6. Zeuzem S, Feinman SV, Rasesnack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl J Med 2000; 343 (1): 666-1672
7. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347: 975-982
8. Fargion S, Fracanzani AL, Valenti L. Treatment choices for people infected with HCV. J Antimicrob Chemother 2004; 53: 708-712
9. Neri S, Bruno CM, Abate G et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24 (10): 1627-1635
10. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with recent history of intravenous drug abuse. Amer J Gastr 2003; 98 (10): 2281-2288
11. Drakoulis C, Stavropoulou E, Nikitidis E et al. Compliance and response to PEG-IFN alpha and Ribavirin combined treatment of a special category of chronic hepatitis C patients, the ex-users of intravenously administered narcotic substances. Clin Microb Inf 2004; 10: 442
12. Ishak K, Baptista A, Bianchi L et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
13. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
14. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peginterferon alfa-2A(40KD) (Pegasys) in combination with ribavirin (RBV):efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36 (Suppl): 3
15. Davis G, Wong JB, McHutchison JG et al. Early virologic response to treatment with peginterferon alfa 2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652
16. Mohsen AH, Trent HCV study group. The epidemiology of hepatitis C in a UK health regional population of 5.12 milion. Gut 2001; 48: 707-713
17. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005; 11: 86-94
18. Koncova-Fejdiova K, Kazar J, Gazdik F et al. Comparison of the HCV genotypes between active drug users and patients in therapeuitic process in the Slovak Republic in the years 2004-2005. J Clin Virol 2006; 36 (Suppl 2): S109
19. Manns MP, Cornberg M, Wedemeyer H. Current and future treatment of hepatitis C. J Gastroenterol 2001; 20 (Suppl 1): C 49
20. Hadziyannis JS, Sette H, Morgan TR et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-355
21. Zeuzem S, Hulterantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40 (6): 993-999
22. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: 185-194
23. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313
24. Poynard T, McHutchison J, Goodman Z et al. Is an, a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C ALGOVIRC Project Group. Hepatology 2000; 31: 211-218
25. Cheng SJ, Bonis PA, Lau J et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-240
26. Cummings KJ, Lee SM, West ES et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. J Amer Med Ass 2001; 285: 193-199
27. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119: 1385-1396
28. McHutchisonJG, PoynardT, Pianko S etal. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119: 1317-1323
29. Foster GR, Fried MW, Hadziyannis SJ, Chaneac M. Treatment of chronic hepatitis C with peginterferon alfa 2 a (40KD) (Pegasys) and ribavirin (Copegus): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology 2003; 38 (Suppl 1): 246A
30. Lucidarme D, Dumas F, Arpurt JP et al. Age at the time of hepatitis C contamination might be an important predictive factor of progression to cirrhosis. Presse Medicale 1998; 27: 608-611
31. Dalgard O, Bjoro K, Helium KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot Study. Hepatology 2004; 40 (6): 1260-1265
32. Parise ER, Oliveira AC, Conceicao RD et al. Response treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on degree of hepatic fibrosis. Braz J Infect Dis 2006; 10 (2): 78-81
33. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069